Nexpoint Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Nexpoint Asset Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4,500	Closed	-$2.57M	–	172
2021 Q1	$2.57M	Hold	4,500	–	–	0.67%	35
2020 Q4	$2.62M	Hold	4,500	–	–	0.86%	25
2020 Q3	$2.32M	Hold	4,500	–	–	0.52%	33
2020 Q2	$2.03M	Sell	4,500 -1,020	-18%	-$450K	0.46%	43
2020 Q1	$1.94M	Sell	5,520 -500	-8%	-$184K	0.37%	41
2019 Q4	$2.23M	Hold	6,020	–	–	0.17%	79
2019 Q3	$2M	Buy	+6,020	New	+$1.96M	0.12%	126

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nexpoint Asset Management's BIO Position: Q2 2021 in Review

Nexpoint Asset Management sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2021, closing a stake of 4,500 shares — an estimated $2.57M sold.

Nexpoint Asset Management first reported a position in BIO in Q3 2019 and held it in 7 quarters. The position peaked at $2.62M in Q4 2020. 509 funds tracked by Wall St. Rank hold BIO as of Q2 2021.

Nexpoint Asset Management reported no remaining Bio-Rad Laboratories Class A position as of Q2 2021 after selling out during the quarter.
Nexpoint Asset Management sold 4,500 Bio-Rad Laboratories Class A shares in Q2 2021, an estimated $2.57M.
Nexpoint Asset Management first reported a position in Bio-Rad Laboratories Class A in Q3 2019 and held it in 7 quarters.
Nexpoint Asset Management's Bio-Rad Laboratories Class A position peaked at $2.62M in Q4 2020.
509 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2021.

Based on Nexpoint Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.